However, addition of bortezomib to R-CHOP or replacement of vincristine by bortezomib (VR-CAP) did not improve both response rates and long-term survival outcomes in patients with non-GCB DLBCL [4]. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.